Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xlife Sciences Ltd. ( (CH:XLS) ) just unveiled an announcement.
Xlife Sciences AG has named twelve project companies that will be partnered with Mexican pharmaceutical group Grupo Landsteiner as part of a planned US-based vehicle intended for a NASDAQ listing in 2026, combining technology platforms, biotech and therapy ventures, medical technology firms and an AI specialist under a scalable structure. The company emphasises that no operational changes are expected for the project companies, which stand to benefit from Grupo Landsteiner’s industrial expertise and international reach, while separately announcing that portfolio company VERAXA Biotech AG has resolved outstanding formalities with authorities and auditors and is moving ahead with an extraordinary general meeting in early 2026 as it prepares for heightened investor engagement, underscoring 2026 as a pivotal year in Xlife’s portfolio development strategy.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss life sciences incubator and accelerator focused on advancing and commercialising promising research projects from universities and other institutions. The company targets solutions for high unmet medical needs and improved quality of life, progressing selected projects in technology platforms, biotechnology and therapies, medical technology and artificial intelligence/digital health towards market readiness and participating in their subsequent value growth.
Average Trading Volume: 6,382
Technical Sentiment Signal: Buy
Current Market Cap: CHF141.9M
See more insights into XLS stock on TipRanks’ Stock Analysis page.